446 related articles for article (PubMed ID: 31529622)
21. Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis.
Maiti R; Mishra A; Puliappadamb HM; Jena M; Srinivasan A
J Clin Pharmacol; 2021 Dec; 61(12):1534-1544. PubMed ID: 34472095
[TBL] [Abstract][Full Text] [Related]
22. Lasmiditan: First Approval.
Lamb YN
Drugs; 2019 Dec; 79(18):1989-1996. PubMed ID: 31749059
[TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
Raffaelli B; Israel H; Neeb L; Reuter U
Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.
MacGregor EA; Komori M; Krege JH; Baygani S; Vincent M; Pavlovic J; Igarashi H
Cephalalgia; 2022 Dec; 42(14):1467-1475. PubMed ID: 35979677
[TBL] [Abstract][Full Text] [Related]
25. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
Reuter U; Krege JH; Lombard L; Gomez Valderas E; Krikke-Workel J; Dell-Agnello G; Dowsett SA; Buse DC
Cephalalgia; 2022 Jan; 42(1):20-30. PubMed ID: 34644189
[TBL] [Abstract][Full Text] [Related]
26. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.
Ashina M; Reuter U; Smith T; Krikke-Workel J; Klise SR; Bragg S; Doty EG; Dowsett SA; Lin Q; Krege JH
Cephalalgia; 2021 Mar; 41(3):294-304. PubMed ID: 33541117
[TBL] [Abstract][Full Text] [Related]
27. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
[TBL] [Abstract][Full Text] [Related]
28. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
29. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.
Tfelt-Hansen PC; Olesen J
J Headache Pain; 2012 Jun; 13(4):271-5. PubMed ID: 22430431
[TBL] [Abstract][Full Text] [Related]
30. Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain.
Peres MFP; Vasudeva R; Baygani SK; Dennehy EB; Vincent M; Friedman DI
Curr Med Res Opin; 2021 Jun; 37(6):1031-1038. PubMed ID: 33784930
[TBL] [Abstract][Full Text] [Related]
31. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
Polavieja P; Belger M; Venkata SK; Wilhelm S; Johansson E
J Headache Pain; 2022 Jul; 23(1):76. PubMed ID: 35790906
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial.
Takeshima T; Komori M; Tanji Y; Ozeki A; Tatsuoka Y
Adv Ther; 2022 Nov; 39(11):5274-5288. PubMed ID: 36138260
[TBL] [Abstract][Full Text] [Related]
33. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
Lipton RB; Lombard L; Ruff DD; Krege JH; Loo LS; Buchanan A; Melby TE; Buse DC
J Headache Pain; 2020 Feb; 21(1):20. PubMed ID: 32093628
[TBL] [Abstract][Full Text] [Related]
34. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
35. Migraine history and response to lasmiditan across racial and ethnic groups.
Charleston L; Savage-Edwards B; Bragg SM; Baygani SK; Dennehy EB
Curr Med Res Opin; 2022 May; 38(5):721-730. PubMed ID: 35350937
[TBL] [Abstract][Full Text] [Related]
36. Lasmiditan Is a New Option for Acute Migraine Treatment.
Blakely KK; Stallworth K
Nurs Womens Health; 2020 Aug; 24(4):294-299. PubMed ID: 32663443
[TBL] [Abstract][Full Text] [Related]
37. Exploration of Lasmiditan 200 mg Versus 100 mg for the Treatment of Migraine: A Meta-analysis Based on Aggregate Data.
Wang T; Feng Y
Clin Neuropharmacol; 2024 Mar-Apr 01; 47(2):44-47. PubMed ID: 38478364
[TBL] [Abstract][Full Text] [Related]
38. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
[TBL] [Abstract][Full Text] [Related]
39. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
[TBL] [Abstract][Full Text] [Related]
40. The Efficacy of Lasmiditan for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies.
Zhu H; Tang Y; Zhou T; Song J
Clin Neuropharmacol; 2020; 43(6):191-195. PubMed ID: 32969971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
